Comparison of LMWH Versus UFH for Hemorrhage and Hospital Mortality in the Treatment of Acute Massive Pulmonary Thromboembolism After Thrombolytic Treatment Randomized Controlled Parallel Group Study

Ucar E. Y., Akgün M., Araz Ö., Tas H., Kerget B., Meral M., ...More

LUNG, vol.193, no.1, pp.121-127, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 193 Issue: 1
  • Publication Date: 2015
  • Doi Number: 10.1007/s00408-014-9660-z
  • Journal Name: LUNG
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.121-127
  • Keywords: Pulmonary thromboembolism, Thrombolytic treatment, Low molecular weight heparin, Unfractionated heparin, Mortality, MOLECULAR-WEIGHT HEPARIN, UNFRACTIONATED HEPARIN, EMBOLISM, MANAGEMENT, THERAPY, RISK, METAANALYSIS, THROMBOSIS
  • Ataturk University Affiliated: Yes


Current guidelines recommend the use of low molecular weight heparin (LMWH) for most haemodynamically stable patients with pulmonary thromboembolism (PTE), however, it is not clear whether LMWH is preferable to unfractionated heparin (UFH) for the treatment of massive PTE. We aimed to compare the use of LMWH versus UFH after thrombolytic treatment in the management of acute massive PTE for hemorrhage and hospital mortality.